Table 3.

Risk of adenoma according to celecoxib treatment, stratified by hsCRP levela

PlaceboCelecoxib, 200 mg bidCelecoxib, 400 mg bid
All patients, no. at risk563558559
 Cumulative incidence, 3 y, % ± SE55 ± 230 ± 233 ± 2
 RR (95% CI)1 (ref)0.60 (0.50–0.72)0.49 (0.40–0.59)
P<0.001<0.001
Patients with hsCRP <3, no. at risk401387378
 Cumulative incidence, 3 y, % ± SE53 ± 339 ± 335 ± 3
 RR (95% CI)1 (ref)0.62 (0.52–0.75)0.54 (0.44–0.65)
P<0.001<0.001
Patients with hsCRP ≥3, no. at risk162171181
 Cumulative incidence, 3 y, % ± SE57 ± 437 ± 430 ± 4
 RR (95% CI)1 (ref)0.48 (0.36–0.65)0.41 (0.30–0.55)
P<0.001<0.001
Pinteraction0.500.58
  • aNo. at risk includes patients who underwent a follow-up colonoscopy at years 1 and/or 3. A patient with a colonoscopy at year 3 but with no colonoscopy at year 1 was included in the analysis through year 1, with the assumption that the patient had no adenoma at year 1, and was then included in the analysis through year 3 according to the findings of the colonoscopy at year 3. The analyses at year 3 excluded patients with an adenoma at year 1 colonoscopy and patients with no adenoma at year 1 and no colonoscopy at year 3 (4). All RRs are multivariate-adjusted as described in the methods. P values for interaction were assessed by using cross-product terms for each celecoxib treatment group and each hsCRP strata.